Good Distribution Practice for Veterinary Medicines

Understanding Good Distribution Practice for Veterinary Medicines in Great Britain

In June 2025, the Veterinary Medicines Directorate (VMD) introduced the Good Distribution Practice (GDP) for Veterinary Medicinal Products in Great Britain guidelines.

This move brings greater regulatory clarity and consistency to a sector that has historically operated under an adaptation of standards relating to medicinal products for human use. For veterinary wholesaler distributors, the new guidance signals not only compliance obligations but also an opportunity to modernise operations, strengthen documentation, and improve Quality Management Systems (QMS) across the supply chain. For those already familiar with the EU GDP Guidelines for human medicinal products, the principles of GDP will feel broadly familiar.

However, the VMD’s version introduces subtle but important distinctions that reflect the unique realities of veterinary medicine distribution. Veterinary medicine supply chains are generally smaller, more varied, and often more complex. Understanding those differences and embedding them effectively into your organisation’s QMS is now critical to maintaining your Wholesale Distribution Authorisation for Veterinary Medicines (WDA(V)) and passing future regulatory inspections.

A New Framework for Veterinary Wholesalers

Under the Veterinary Medicines Regulations (VMR) 2013, anyone who distributes veterinary medicinal products by wholesale in Great Britain must hold a Wholesale Dealer’s Authorisation (WDA(V)).

The new GDP guidance, published by the VMD, defines the standards expected of those licence holders. It covers every stage of the supply chain, from sourcing and storage through to dispatch, transport, returns and recalls, mirroring the comprehensive structure long established in the human pharmaceutical sector. At its heart, the guidance reinforces that every wholesaler must operate within a robust, documented Quality Management System (QMS) that ensures medicinal products are consistently handled, stored, and distributed under conditions that safeguard their quality and integrity.

The VMD expects senior leaders to demonstrate clear commitment to quality, define responsibilities, and ensure continuous improvement. In practical terms, that means integrating GDP compliance into everyday operations rather than treating it as a separate regulatory exercise.

The guidance also sets detailed expectations for premises, equipment, personnel, documentation, and transport:

• • Facilities must be suitable for purpose, environmentally controlled, and regularly mapped to verify temperature uniformity.
  • Equipment must be maintained and calibrated, and transport processes must be validated to ensure products remain within defined temperature ranges throughout transit.
  • Personnel must be appropriately trained and competent, with clear role definitions and ongoing development plans.
  • Transportation of veterinary medicines must protect the quality and integrity of the product.
  • Every process must be traceable and supported by accurate, contemporaneous documentation and records which can withstand regulatory inspection scrutiny.

The Role and Responsibilities of the Wholesale Qualified Person

One of the most significant features of the veterinary GDP framework is the designation of a Wholesale Qualified Person (WQP), the veterinary GDP equivalent of the WDA(H) Responsible Person, who carries ultimate responsibility for ensuring that every aspect of storage and distribution meets the required standards.

The WQP role is analogous to the Responsible Person (RP) defined under human GDP, but the VMD’s expectations introduce some distinct nuances. Each WQP named on a WDA(V) must personally conduct, or oversee, at least one self-inspection per year covering the full scope of authorised activities. As with the GDP RP, a WQP may nominate a deputy to carry out specific duties, but the overall responsibility remains with the WQP.

How Veterinary GDP Differs from Human GDP

While the overall objectives of both frameworks are the same, ensuring the quality and integrity of the medicinal product and protecting patient safety, veterinary GDP differs in several ways.

First, veterinary distribution operates in a more diverse and often fragmented marketplace. Products range from vaccines and antibiotics for companion animals to biologics for livestock and niche treatments for exotic species. The scale and variability of this sector mean that storage and transport practices must be more flexible. The VMD’s guidance recognises this, allowing greater use of risk-based approaches to activities such as returns management and transport validation, provided those risks are assessed, documented, and justified.

Second, veterinary wholesalers must navigate unique regulatory requirements relating to import certificates and product authorisations. While human medicines distribution is governed by long established import and parallel trade frameworks, the veterinary sector is still adjusting to post-Brexit rules. Any veterinary medicinal product that is not licensed in Great Britain must be supported by a valid import certificate before it can be distributed. This introduces additional documentation and verification requirements, especially for wholesalers operating cross-border between Great Britain, Northern Ireland, and the EU.

Another notable difference lies in the handling of returns and re-use decisions.

The VMD guidance deliberately avoids setting rigid timelines for evaluating and reintroducing returned, non-defective products into stock. Instead, it requires wholesalers to adopt a risk-based justification for every such decision. While this flexibility can be beneficial, it also increases the importance of transparent documentation. Inspectors will expect to see clear evidence of decision-making logic, risk assessment, and traceability.

Finally, for WDA(V) holders where no WDA(H) is in place, veterinary GDP inspections are conducted by the VMD rather than the MHRA, and the inspection cycle is slightly different. Sites will generally be inspected on a risk-based frequency not exceeding five years, though this can vary depending on performance and complexity.

For companies that handle both human and veterinary products, the MHRA generally undertake the regulatory inspections inline with the schedule for the WDA(H) GDP operations.

Emerging Issues and Documentation Challenges

For many veterinary distributors, implementing the new GDP guidance will not mean starting from scratch.
Most already have systems based on human GDP principles, particularly those that also handle human medicines or active substances. The challenge lies in adapting those systems to reflect the specific language and expectations of the VMD guidance. Paradigm Shift consultants can help with this.

Documentation remains the most common source of noncompliance. Inspectors continue to identify weaknesses such as inconsistent record keeping, missing signatures, incomplete temperature logs, or poorly controlled document versions. In a digital age, data integrity is under the microscope. Whether records are paper-based or electronic, companies must be able to demonstrate authenticity, accuracy, and traceability throughout the product life cycle.

Another growing area of scrutiny is temperature control during transport.
Veterinary wholesalers frequently handle smaller consignments and irregular routes, sometimes using third-party logistics providers who may not specialise in medicinal product handling. The VMD expects wholesalers to take full responsibility for ensuring that their transport partners meet GDP standards, this can be achieved with written agreements, audits, and validation of packaging and transport routes.

The management of returns, complaints, and suspected counterfeit / falsified medicines is another area requiring careful attention. Wholesalers must have clear, documented processes for identifying, quarantining, and investigating any suspect product, and for notifying the VMD promptly of confirmed cases.

Quality Management and the Importance of Self-Inspection

Each WQP must ensure that their site conducts thorough internal audits covering all aspects of GDP compliance.
These audits should not be viewed as box-ticking exercises but as opportunities for continuous improvement. Findings must be documented, root causes analysed, and corrective actions tracked through to closure.

Many of the deficiencies identified in VMD inspections stem not from lack of awareness but from weak internal follow-up.
By embedding self-inspection into the QMS as a live process, rather than an annual ritual, wholesalers can detect problems early and maintain confidence in their compliance posture. Paradigm Shift Consulting’s experience across the pharmaceutical sector has shown that the most resilient organisations are those that treat inspection readiness as a continuous state, not a project.

The Post-Brexit Context and Future Outlook

The regulatory landscape for veterinary medicines is still evolving with further changes expected in early 2026.
Supply routes, import certification, and mutual recognition of inspections are all active policy areas under review by the VMD. Wholesalers should therefore view compliance not as a static target but as a moving framework that demands continual monitoring of official updates and guidance.

Meanwhile, the VMD and MHRA continue to collaborate to ensure coherence between human and veterinary distribution standards. Over time, we can expect closer alignment in principles and inspection methodology, even if specific requirements remain tailored to their respective markets.

In Summary

The introduction of the new Good Distribution Practice for Veterinary Medicinal Products in Great Britain marks a defining moment for the veterinary supply chain.
It brings the sector firmly into the modern regulatory era, emphasising documentation, risk management, data integrity, and accountability. While these expectations undoubtedly increase the administrative and operational demands on wholesalers, they also offer a clear route to improved quality, reduced risk, and greater market credibility.

A culture of quality and transparency enhances relationships with manufacturers, veterinarians, and regulators alike. It builds trust, resilience, and long-term sustainability in an increasingly complex and competitive marketplace.

At Paradigm Shift Consulting, we see this as part of a broader transformation across the life sciences and animal health industries. As with human GDP, the goal is not simply to meet regulatory requirements, but to elevate the standards of practice that protect both human and animal health.

The paradigm is shifting! Those who adapt early will set the benchmark for the next decade of veterinary pharmaceutical distribution.

Help and Support

Unsure whether your QMS is compliant with Veterinary Medicine GDP guidelines? Worried about the current status of your QMS? Is your next VMD inspection due in the coming months? Do you need help reviewing your operations for compliance? Would you like support preparing for your next inspection? 

Our team of experienced quality specialists can help. Contact us  for more information and a free consultation.